Introducing allogeneic serum eyedrops

Australian Red Cross Lifeblood is excited to announce the launch of our new Allogeneic Serum Eye Drops (AlloSED) commencing February 2026. 
Manufactured from the generous donations of our male Group AB donors and delivered directly to the patient – our new AlloSED product and service model makes serum eyedrops more efficient to produce, and available to more patients nationally.

What is changing?

The National Blood Authority (NBA) has approved the introduction of AlloSED, to replace both Autologous (AutoSED) and Patient-Tailored (PT SED) Serum Eye Drops, under the provisions of the Deed of Agreement for supply of blood products and services to the Australian community. 
Lifeblood is also implementing a new service model, and all approved AlloSED orders will be delivered directly to patients. 

What do you need to do?

•    Please see our ‘letter to ophthalmologists’ and note the detail and timelines associated with the transition from AutoSED and PT SED to the new AlloSED product.
•    Please refer to ‘Clinical indications for ordering serum eyedrops from the Australian Red Cross Lifeblood’ for patient eligibility for AlloSED.
•    Note that additional information relating to the process for requesting AlloSED will be communicated in the coming weeks.

We thank you again and ask your support in sharing this communication with all relevant stakeholders within your organisation. 

For any enquiries regarding this change, please contact Lifeblood Medical Services on 1300 669 054.